Bijan Nejadnik, M.D., Chief Medical Officer and Head of Research

Mountain View, CA

(TSE: 4592)

Virtual Presentation

SanBio is engaged in the regenerative cell medicine business, spanning research, development, manufacture, and sales of regenerative cell medicines. The company’s propriety regenerative cell medicine product, SB623, is currently being investigated for the treatment of several conditions including chronic neurological motor deficit resulting from traumatic brain injury and stroke. SanBio is preparing to file a Biologics License Application with the PMDA in Japan for SB623 for the treatment of chronic motor deficits resulting from traumatic brain injury, while also making progress in its global development program. Further, the company is working toward commencing clinical trials of SB623 for stroke in Japan. SB623 has been granted Sakigake designation for innovative medical products from the Ministry of Health, Labour, and Welfare of Japan, RMAT designation from the U.S. Food and Drug Administration, and the Advanced Therapy Medicinal Product classification from the European Medicines Agency.

By using this website you agree to accept our Privacy Policy and Terms & Conditions